Similar to olaparib, rucaparib was approved by the FDA—but not by the EMA—for the treatment of metastatic castration-resistant prostate cancer patients with germline and/or somatic BRCA1/2 mutations, who progressed on AR signaling inhibitor or taxane. The gene discussed is BRCA1; the disease is prostate cancer.